HOME Press Releases Vascular Stents Market worth USD 17.68 Billion by 2021



Vascular Stents Market worth USD 17.68 Billion by 2021


The report Vascular Stent Market by Type (BMS, BVS, Drug Eluting), Product (Coronary, Peripheral, Carotid, Femoral, Aortic Aneurysm), Material [Metal (Stainless Steel, PtCr, Nitinol), Polymer], End User (Hospital, Cardiology Center, ASC)- Global Forecast to 2021” analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia, and the Rest of the World (RoW).

     Download PDF Brochure     Speak to Analyst     Inquiry Before Buying

Browse 138 market data tables and 76 figures spread through 189 pages and in-depth TOC on “Vascular Stent Market by Type (BMS, BVS, Drug Eluting), Product (Coronary, Peripheral, Carotid, Femoral, Aortic Aneurysm), Material [Metal (Stainless Steel, PtCr, Nitinol), Polymer], End User (Hospital, Cardiology Center, ASC)- Global Forecast to 2021”
http://www.marketsandmarkets.com/Market-Reports/vascular-stent-market-199869009.html
Early buyers will receive a 10% customization on reports.

The global vascular stents market is projected to reach USD 17.68 billion by 2021 from USD 12.21 billion in 2016, at a CAGR of 7.7% during the forecast period.

The growth of this market is majorly driven by the technological advancements in stents, increasing number of angioplasty procedures, rising burden of vascular diseases, increasing demand for minimally invasive procedures, and rising geriatric population. However, the presence of alternative treatment methods for vascular diseases, stringent regulations for product approval, and numerous cases of product failure and product recalls are expected to restrain the growth of the vascular stents market during the forecast period of 2016 to 2021.

This report segments the vascular stents market based on product, type, mode of delivery, material, end user, and region. Based on type, the market is segmented into bare-metal stents, drug-eluting stents, and bioabsorbable stents. The drug-eluting stents segment is expected to account for the largest share of the vascular stents market in 2016. This can primarily be attributed to the advantages of drug-eluting stents over bare-metal stents, such as lower risk of restenosis and other related complications.  Based on the mode of delivery, the vascular stents market is segmented into balloon-expandable stents and self-expanding stents. The balloon-expandable stents segment is expected to grow at the highest CAGR during the forecast period primarily due to the growing regulatory approvals for balloon-expandable stents and the high usage of these stents in angioplasty procedures.

Based on region, the vascular stents market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America was the largest market for vascular stents in 2016. However, the Asian market is projected to register the highest growth during the forecast period. Factors such as the large population base, growing prevalence of cardiovascular diseases, rising adoption of advanced technologies, and the low manufacturing costs for medical devices in emerging Asian countries are expected to drive the growth of the Asian market during the forecast period.

Several big and emerging players are operating in the vascular stents market, making it highly fragmented. The key players operating in this market include Medtronic, plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), W. L. Gore and Associates (U.S.), C. R. Bard (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Translumina GmbH (Germany), and JOTEC GmbH (Germany).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

 

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports